Praluent (alirocumab)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Praluent (alirocumab), covering 2015-08-31 to 2017-03-21. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1) [Phase 3]